达格列净在难治性心力衰竭伴射血分数降低的非压实性心肌病中的作用:不稳定障碍的第四大支柱

Pankaj V. Jariwala , Dilip Gude
{"title":"达格列净在难治性心力衰竭伴射血分数降低的非压实性心肌病中的作用:不稳定障碍的第四大支柱","authors":"Pankaj V. Jariwala ,&nbsp;Dilip Gude","doi":"10.1016/j.ihjccr.2022.11.004","DOIUrl":null,"url":null,"abstract":"<div><p>Dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, has been shown in the <strong><em>Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) study</em></strong> to significantly decrease mortality or hospitalisation in patients with heart failure with reduced ejection fraction (HFrEF). We describe a case of a patient with noncompaction cardiomyopathy (NCCM) who initially responded partially to guideline-directed medical therapy, which included an angiotensin receptor-neprilysin inhibitor (ARNI). However, the patient's symptoms returned, and the addition of dapagliflozin was able to provide a definitive improvement in his clinical-echocardiographic parameters. There is currently no data indicating that dapagliflozin is beneficial for patients with NCCM and HFrEF which progressive disorder.</p></div>","PeriodicalId":100653,"journal":{"name":"IHJ Cardiovascular Case Reports (CVCR)","volume":"6 4","pages":"Pages 158-162"},"PeriodicalIF":0.0000,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2468600X22000676/pdfft?md5=05e1725620d2b1c3c90a8adaf2b4cdf4&pid=1-s2.0-S2468600X22000676-main.pdf","citationCount":"0","resultStr":"{\"title\":\"The role of dapagliflozin in non-compaction cardiomyopathy for refractory heart failure with reduced ejection fraction: 4th pillar for unstable disorder\",\"authors\":\"Pankaj V. Jariwala ,&nbsp;Dilip Gude\",\"doi\":\"10.1016/j.ihjccr.2022.11.004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, has been shown in the <strong><em>Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) study</em></strong> to significantly decrease mortality or hospitalisation in patients with heart failure with reduced ejection fraction (HFrEF). We describe a case of a patient with noncompaction cardiomyopathy (NCCM) who initially responded partially to guideline-directed medical therapy, which included an angiotensin receptor-neprilysin inhibitor (ARNI). However, the patient's symptoms returned, and the addition of dapagliflozin was able to provide a definitive improvement in his clinical-echocardiographic parameters. There is currently no data indicating that dapagliflozin is beneficial for patients with NCCM and HFrEF which progressive disorder.</p></div>\",\"PeriodicalId\":100653,\"journal\":{\"name\":\"IHJ Cardiovascular Case Reports (CVCR)\",\"volume\":\"6 4\",\"pages\":\"Pages 158-162\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2468600X22000676/pdfft?md5=05e1725620d2b1c3c90a8adaf2b4cdf4&pid=1-s2.0-S2468600X22000676-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"IHJ Cardiovascular Case Reports (CVCR)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2468600X22000676\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"IHJ Cardiovascular Case Reports (CVCR)","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468600X22000676","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

达格列净是一种钠-葡萄糖共转运蛋白-2抑制剂,在达格列净和预防心力衰竭不良结局(DAPA-HF)研究中显示,达格列净可显著降低射血分数降低(HFrEF)心力衰竭患者的死亡率或住院率。我们描述了一例患有非压实性心肌病(NCCM)的患者,他最初对指南指导的药物治疗有部分反应,其中包括血管紧张素受体-neprilysin抑制剂(ARNI)。然而,患者的症状又出现了,添加达格列净能够提供他的临床超声心动图参数的明确改善。目前没有数据表明达格列净对进行性疾病的NCCM和HFrEF患者有益。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The role of dapagliflozin in non-compaction cardiomyopathy for refractory heart failure with reduced ejection fraction: 4th pillar for unstable disorder

Dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, has been shown in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) study to significantly decrease mortality or hospitalisation in patients with heart failure with reduced ejection fraction (HFrEF). We describe a case of a patient with noncompaction cardiomyopathy (NCCM) who initially responded partially to guideline-directed medical therapy, which included an angiotensin receptor-neprilysin inhibitor (ARNI). However, the patient's symptoms returned, and the addition of dapagliflozin was able to provide a definitive improvement in his clinical-echocardiographic parameters. There is currently no data indicating that dapagliflozin is beneficial for patients with NCCM and HFrEF which progressive disorder.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信